MedicalResearch.com Interview with: Marc Ellsworth, M.D Neonatology fellow at the Mayo Clinic Children’s Center MedicalResearch: What is the background for this study? Dr. Ellsworth: Inhaled Nitric Oxide (iNO) is a drug that has FDA approval for use in neonates >34 … Continue reading →... Read more »
MedicalResearch.com Interview with:, & Marc Ellsworth, M.D. (2015) Inhaled Nitric Oxide Still Used Off-Label In Preterm Infants. MedicalResearch.com. info:/
MedicalResearch.com Interview with: Hallie Prescott, MD, MSc Clinical Lecturer, Internal Medicine Division of Pulmonary & Critical Care Medicine University of Michigan Health System Ann Arbor, MI 48109-2800 Medical Research: What is the background for this study? What are the … Continue reading →... Read more »
MedicalResearch.com Interview with:, & Hallie Prescott, MD, MSc. (2015) Personalized Risk Calculations May Reduce Readmissions Of Sepsis Survivors. MedicalResearch.com. info:/
MedicalResearch.com Medical Research Interviews and News
MedicalResearch.com Interview with: Dr. Cornejo-Juárez Department of Infectious Disease, Instituto Nacional de Cancerología Tlalpan Mexico MedicalResearch: What is the background for this study? Dr. Cornejo: Critically ill patients in the intensive care unit are at major risk of hospital-acquired infections. … Continue reading →
The post Multidrug Resistant Bacteria Found Commonly In Oncology Intensive Care appeared first on........ Read more »
MedicalResearch.com Interview with:, & Dr. Cornejo-Juárez. (2015) Multidrug Resistant Bacteria Found Commonly In Oncology Intensive Care. MedicalResearch.com. info:/
The fourth rule of Expensive Scare Medicine: 'If you measure something and it is not normal, make it normal if it is safe to do so'. But beware! This can lead to a dangerous and insatiable desire for 'euboxia' - the pathophysiological state whereby 'all boxes on a pathology print-out are in the normal range'.... Read more »
Reade MC. (2009) Should we question if something works just because we don't know how it works?. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 11(4), 235-6. PMID: 20001869
Xigris, or "recombinant human activated Protein C," is an anticoagulant used to treat septic shock. How does Xigris work?What does Protein C do?Protein C is a key component of the body’s natural negative feedback loop for the coagulation cascade. The final steps in coagulation are the conversion of Prothrombin to Thrombin by Factor X and Factor V. Factor X is activated by Factor VIII.Thrombin produces Fibrin, which is the building block of blood clots, but it also activates Protein C (PC) b........ Read more »
Goda Choi, Jorrit-Jan H. Hofstra, Joris J. T. H. Roelofs, Sandrine Florquin, Paul Bresser, Marcel Levi, Tom van der Poll, & Marcus J. Schultz. (2007) Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Critical Care Medicine, 35(5), 1362-1368. DOI: 10.1097/01.CCM.0000261888.32654.6D
Do you write about peer-reviewed research in your blog? Use ResearchBlogging.org to make it easy for your readers — and others from around the world — to find your serious posts about academic research.
If you don't have a blog, you can still use our site to learn about fascinating developments in cutting-edge research from around the world.
Research Blogging is powered by SMG Technology.
To learn more, visit seedmediagroup.com.